Proactive Strategies For Meeting NDA Timelines Despite Last Minute Supplemental Study Requests
With just months left until planned submission of a new drug application (NDA), the Food and Drug Administration mandated a series of unexpected supplemental studies for a new oncology drug. They needed to document the effect of a low-fat diet on the study drug pharmacokinetics, drug-drug interactions, impact on QT interval, and liver and kidney metabolism.
Learn having a CRO that is experienced in the common FDA-required studies for NDA submission can make or break the submission timeline. Nimble responses and expert logistics setups can make all the difference.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Hydrocarbon Online? Subscribe today.
Subscribe to Hydrocarbon Online
X
Subscribe to Hydrocarbon Online
This website uses cookies to ensure you get the best experience on our website. Learn more